Peter Humphrey, MD, PhD, Talks Multidisciplinary Aspects of Oncology Research

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about how the conference catered to the multidisciplinary audience, and what he learned from that.

CancerNetwork® spoke with Peter Humphrey, MD, PhD, professor of pathology and director of Genitourinary Pathology at Yale School of Medicine in New Haven, Connecticut, about how he felt the multidisciplinary nature of the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, hosted by Physicians’ Education Resource®, LLC (PER®) was useful for future practice. Humphrey also talked about utilizing tumor boards where clinicians from different departments can discuss current topics.


One of the reasons I so enjoy this conference is the multidisciplinary nature. There’s directional learning and I’ve learned so much from my clinical colleagues today about their management based upon our diagnosis, for example. I think the same is true for when we present our diagnostic approach and how that diagnosis would influence them and their patient management. That multidisciplinary nature [for] taking care of patients with cancer, any cancer, is so vital.

I also appreciate that locally at Yale where we have weekly tumor boards, we have interactions amongst all of us including medical oncologists, urologist, interventional radiologists, diagnostic radiologists, and pathologists. Only by all of all of us having an input can we get a complete picture of the patient’s status at that point in time and have a vibrant discussion about treatment options. Depending upon the diagnosis and what radiologists and pathologists see at that point in time and in the patient’s care, it’s [providing] ongoing medical education for everyone while at the same time being practical in care of the patient.

Related Videos
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.
The use of palliative care in ovarian cancer resulted in a decrease in overall readmissions and index hospitalization costs.
Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
Experts on RCC
Experts on RCC
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Related Content